Corcept Therapeutics
CORT
$24.59
Share price
-1.88%
Change (1 day)
9.83%
Change (1 year)
Categories
P/S ratio for Corcept Therapeutics (CORT)
P/S ratio as of May 2024 (TTM): 5.39
According to Corcept Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.39447. At the end of 2023 the company had a P/S ratio of 6.94.
P/S ratio history for Corcept Therapeutics from 2007 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 6.94 | 27.57% |
| 2022 | 5.44 | -12.9% |
| 2021 | 6.25 | -27.27% |
| 2020 | 8.59 | 89.9% |
| 2019 | 4.52 | -26.07% |
| 2018 | 6.12 | -52.75% |
| 2017 | 12.9 | 30.61% |
| 2016 | 9.91 | -8.71% |
| 2015 | 10.9 | -5.22% |
| 2014 | 11.5 | -62.98% |
| 2013 | 30.9 | -28.3% |
| 2012 | 43.2 | |
| 2011 | N/A | |
| 2010 | N/A | -100% |
| 2009 | > 1000 | 6549.54% |
| 2008 | 87.1 | -60.46% |
| 2007 | 220 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.88 | -28.10% | 🇺🇸 USA |
 Novartis NVS | 3.98 | -26.25% | 🇨🇭 Switzerland |
 Pfizer PFE | 2.68 | -50.29% | 🇺🇸 USA |
 Eli Lilly LLY | 21.1 | 290.27% | 🇺🇸 USA |
 Merck MRK | 5.40 | 0.19% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 1.95 | -63.94% | 🇺🇸 USA |
 MannKind Corp MNKD | 5.96 | 10.50% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | 3.35 | -37.83% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 6.58 | 21.93% | 🇺🇸 USA |